Prime Medicine, Inc. Equity Securities, FV-NI, Unrealized Loss
Prime Medicine, Inc. (PRME) reported Equity Securities, FV-NI, Unrealized Loss of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2023-03-09
- Prime Medicine, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2022-12-31 was $0.00.
- Prime Medicine, Inc. equity securities, fv-ni, unrealized loss for fiscal 2022 was $0.00.
- Prime Medicine, Inc. equity securities, fv-ni, unrealized loss for fiscal 2021 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |